000058755460
BLOOD CANCER OXR – FINAL REPORTOncoBREAST Dx
Patient Information
Identification Data General Biochemistry Blood Drawn Realization
HRN: BRE0027555273 Creatinine (mg/dL): 1.00 Blood Drawn Date: 22-06-2024
Name: Mohan Kumar ASAT (U/L): 8.00
ALAT (U/L): 12.00 Urine Tumor Markers
Personal Data GGT (U/L): 7.00 8-OHdG (ng/mL): 11.10
Age (years): 23 Total Bilirubin (mg/dL): 1.00
Hemolized Sample: No Urine Drawn Realization
Comorbidities Urine Drawn Date: 22-06-2024
Atherosclerosis: No Serum Tumor Markers
Chronic Liver Disease: Yes CA 15.3 (U/mL): 19.70 Lifestyle
Diabetes Mellitus 1 or 2: No CEA (ng/mL): 1.60 Smoking: Negative
Jaundice: No EGFR (ng/mL): 5.00
Renal Failure: Yes NGAL (ng/mL): 4.60
NSE (ng/mL): 7.00
Outcome
Results
Some Tumor Markers are outside the reference range and suggest malignancy.
“High”
Range: Low, Moderate, High
Comments
In absence of comorbidities that are well-known source of False Positive (FP) in healthy patients by
increasing some Tumor Markers levels, whole Tumor Markers levels suggest malignancy.
Conclusions
WE SUGGEST BLOOD CANCER. THE 2016 ICD-10-CM DIAGNOSIS CODE IS C50 (MALIGNANT
NEOPLASM OF BLOOD).
This report has been generated from the data entered on 25-06-2024 10:55:02 UTC/GMT.
Disclaimer
This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Blood Cancer has been developed for the
exclusive use by healthcare professionals, and solely as a Clinical Decision Support System (CDSS), not
as an unique element for diagnosis. The algorithm bears a Sensitivity = 82.3%, Specificity = 85.7%. Please
note, negativity of the Tumor Markers does not exclude at 100% the possibility of a malignant epithelial
tumor.
Christian Medical College, Technical Responsible
Vellore Lorena Lendinez
Email:
[email protected] Chief Scientific Officer
Website: www.friendsoftheroyallondonhospital.org.uk The Royal London Hospital
Powered by TCPDF (www.tcpdf.org)
